Jim Walker Named as Finalist in 2008 American Business Awards
Octagon Research Solutions’,Chairman and Chief Executive Officer Jim Walker was named as a “Best Chairman” finalist in the 2008 American Business Awards.
WAYNE, PA, May, 30, 2008- Octagon Research Solutions, Inc., a pioneer and leading provider of breakthrough software and services to the life sciences industry, today announced that Jim Walker, chairman and chief executive officer, was named as a finalist in the category of “Best Chairman” in the 2008 American Business Awards. The American Business Awards are the only national, all-encompassing awards program honoring great performances in business.
Stevie® Award winners will be announced during the annual gala on Thursday, June 12 at the Marriott Marquis Hotel in New York City. More than 600 executives from across the U.S. are expected to attend. The ceremonies will be broadcast on radio nationwide by the Business TalkRadio Network and hosted by Liz Claman of FOX Business Network.
More than 2600 entries from companies of all sizes and in virtually every industry were submitted for consideration in more than 40 categories, including Best Overall Company, Best Executive, Best New Product or Service, Best Corporate Responsibility Program, and new categories including Best Management Team and Best Corporate Environmental Responsibility Program. Jim Walker will be competing in the Management category for Best Chairman.
Members of the Awards’ Board of Distinguished Judges & Advisors and their staffs will select Stevie Award winners from among Finalists in final judging during the week of May 19. Finalists are chosen by business professionals nationwide during preliminary judging in April through early May.
“ABA entries grew more than 30% this year, so being named a Finalist is more of an accomplishment than ever before,” said Michael Gallagher, founder and president of the Stevie Awards. “It means that independent business executives have agreed that the nominee is worthy of national recognition. We congratulate all of the finalists on their achievement and wish them well in the competition.”
Walker noted, “It is an honored to be a finalist among such accomplished individuals. When Octagon was founded in 1999, our vision was to transform the industry’s view of clinical R&D. That vision has been realized through the dedication and talent of my senior staff and the ability of each Octagon employee to embrace that vision and bring it to reality. I am grateful for the recognition this nomination brings.”
Details about The American Business Awards and the list of Finalists in all categories are available at www.stevieawards.com/aba.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
